More than half (372; 76.5 %) of the patients had estrogen receptor (ER, +)/progesterone receptor (PR, +) breast cancer, 99 (20.4 %) patients had ER(+)/PR(−) breast cancer, and 15 (3.1 %) patients had ER(−)/PR(+) breast cancer. The gene discussed is PGR; the disease is breast carcinoma.